Arcutis Biotherapeutics
ARQT
ARQT
267 hedge funds and large institutions have $3.11B invested in Arcutis Biotherapeutics in 2026 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 104 increasing their positions, 86 reducing their positions, and 47 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
5% less funds holding
Funds holding: 282 → 267 (-15)
17% less capital invested
Capital invested by funds: $3.75B → $3.11B (-$632M)
17% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 47
Holders
267
Holding in Top 10
4
Calls
$9.97M
Puts
$2.28M
Top Buyers
| 1 | +$50.5M | |
| 2 | +$20.6M | |
| 3 | +$16.5M | |
| 4 |
BAMCO Inc
New York
|
+$14.5M |
| 5 |
OAM
Oberweis Asset Management
Lisle,
Illinois
|
+$14.2M |
Top Sellers
| 1 | -$45.4M | |
| 2 | -$18.3M | |
| 3 | -$16.8M | |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$13.8M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$12.3M |
